entertainment -WSS

entertainment

author：Wikipedia 2025-09-30 01:14:58 - browse：87

JOSEPH PREZIOSO/AFP via Getty Images

Late-stage trial results for a pain medication developed by Vertex Pharmaceuticals reinforced experts’ sense that the drug was both safe and offered modest pain relief. But the findings also prompted fresh debate on Tuesday about how widely used the therapy would be should it win regulatory approval.

The company reported that its small molecule drug, VX-548, outperformed placebo in a pair of pain relief trials that recruited patients who had gotten an abdominoplasty (tummy tuck) or bunion surgery. The study also found that the drug was generally safe, with fewer patients on the medication reporting adverse events than those who had taken a placebo. But there was a catch: VX-548 didn’t outperform a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint. And in the bunionectomy study, the opioid comparator beat VX-548 on pain relief.

“While this study was not explicitly designed to test VX-548 vs. the opioid comparator, this may complicate the prescribing decision in the acute setting, where patients often take a short course of treatment and efficacy is a primary consideration,” Stifel market analyst Paul Matteis wrote in a note to investors, adding that results from three Phase 3 studies were positive overall.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Google and Epic fight stronger regulation of AI in health care

leisure time

WSS

Here's how to stay safe from wildfire smoke amid reduced air quality

How dance can help nurses traumatized by Covid

Supreme Court strikes down Biden student loan forgiveness program

UnitedHealth wins $3.3 billion takeover of Amedisys

WHO calls for emergency meeting on new China virus, as cases spread

Here's how to stay safe from wildfire smoke amid reduced air quality

Wikipedia

entertainment

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

The cancer drug shortage isn’t new — and neither are the solutions

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

State Dept. review finds Biden bears some blame for Afghanistan failures

Federal board approves $12.7 billion budget for Puerto Rico as island shakes off bankruptcy

Tori Bowie and the unacceptable rates of Black maternal death

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Peter Hotez and the public health issue of online harassment

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

focus

Thousands protest in Iraq for a second day over burning of Quran in Sweden

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

The simple reason for the increase in autism diagnosis

Biden tests positive for Covid

Listen: Wegovy in the brain & pivotal Alzheimer's data

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

hotspot

focus

leisure time

knowledge